

Date of Birth
9/17/1960 (Age 57)

Sex
Male

Physician
John Brown

Institution
University of Pittsburgh
Medical Center

Specimens Collected
Blood (1/23/18)
Saliva (1/23/18)
Cerebrospinal Fluid (4/24/18)

Biomarkers Collected
DNA-SEQ
RNA-SEQ
MRI
Mass-Spectroscopy
PET-Amyloid
PET-Tau

Notes

This patient has two genetic variants (APOE4, TREM2) known to be highly predictive of developing Alzheimer's Disease.


Amyloid-beta and tau protein levels indicate moderate Alzheimer's pathology.

Patient likely to develop severe cognitive decline in 2-4 years.

GENETIC VARIANTS

Germline		Clinical Significance
APOE4	Increased Alzheimer's risk	Pathogenic
TREM2	Increased Alzheimer's risk	Pathogenic

NEURODEGENERATION MARKERS



CLINICAL TRIAL RECOMMENDATIONS

Therapy Type	Drug Name	Information
AB-antibody	Aducanumab	Biogen, Phase III PMID 11729812
	Gantenerumab	Roche, Phase III PMID 20173421
BACE1 Inhibitor	E2609	Biogen, Phase III PMID 2861532
Antisense Oligonucleotide (tau)	BIIB080	Biogen, Phase I PMID 254829
Tau-antibody	R07105705	Genentech, Phase II PMID 22411983